Previous works demonstrated the successful repurposing of the two synthetic AMPs 19-2.5 and 19-4LF for cutaneous leishmaniasis, when the compounds were administered in solution on skin lesions caused by <i>Leishmania major</i> in a BALB/c mouse model. Here, ADSL is linked to cutaneous leishmaniasis.